Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Nov;29(8):604-6.
doi: 10.1002/dmrr.2435.

Proposal for generating new beta cells in a muted immune environment for type 1 diabetes

Claresa Levetan  1 , Paolo Pozzilli, Lois Jovanovic, Desmond Schatz
Affiliations

Proposal for generating new beta cells in a muted immune environment for type 1 diabetes

Claresa Levetan et al. Diabetes Metab Res Rev. 2013 Nov.

Abstract

Background: Over the past decade, many immune tolerance agents have shown promise in the non-obese diabetic mouse model for prevention and reversal of type 1 diabetes but have not been successful in clinical trials among recently diagnosed type 1 patients. The trials from decades ago using Cyclosporine A in significantly lower dosages than used for organ transplantation and in similar dosages that have increased T regulatory cell populations in conditions such as atopic dermatitis, demonstrated very high initial insulin-free remission rates when administered immediately after diagnosis. Over time, all newly diagnosed type 1 patients given Cyclosporine A required insulin. Human trials with immune tolerance agents suggest that in addition to an immune tolerance agent, a beta cell regeneration agent may also be necessary to induce long-lasting remission among patients with recent onset type 1 diabetes.

Methods: A randomized, double-blind prospective trial among recent onset type 1 diabetes patients has been designed using Cyclosporine A and a proton-pump inhibitor, which increases gastrin levels and has been shown to work through the Reg receptor to transform pancreatic duct cells into islets.

Keywords: beta cell regeneration; immune protection; type 1 diabetes.

PubMed Disclaimer

Figures

Figure 1
Figure 1
A novel proposal to tackle type 1 diabetes at diagnosis
See this image and copyright information in PMC

References

    1. Bougneres PF, Carel JC, Castano L, et al. Factors associated with early remission of type I diabetes in children treated with cyclosporine. N Engl J Med. 1988;17;318(11):663–6670. - PubMed
    1. De Filippo G, Carel JC, Boitard C, et al. Long-term results of early cyclosporin therapy in juvenile IDDM. Diabetes. 1996;45(1):101–104. - PubMed
    1. Assan R, Blanchet F, Feutren G, et al. Normal renal function 8 to 13 years after cyclosporin. A therapy in 285 diabetic patients. Diabetes Metab Res Rev. 2002;18(6):464–472. - PubMed
    1. Brandt C, Pavlovic V, Radbruch A, Worm M, et al. Low-dose cyclosporine. A therapy increases the regulatory T cell population in patients with atopic dermatitis. Allergy. 2009;64(11):1588–1596. - PubMed
    1. Levetan CS, Pierce SM. Distinctions between the islets of mice and men: implications for new therapies for type 1 and 2 diabetes. Endocr Pract. 2013;19(2):301–312. - PubMed

MeSH terms